Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that the U.S. Food and Drug Administration has scheduled a Type C meeting in January 2026 to discuss the clinical pathway for buntanetap in Parkinson’s disease dementia (PDD). The company also reaffirmed continued progress in its Phase 3 Alzheimer’s trial, which remains in full regulatory alignment on design, endpoints and patient population.
CEO Maria Maccecchini said the meeting marks an important milestone for the PDD program, with Senior VP Cheng Fang noting that strong data across Alzheimer’s and Parkinson’s studies highlights buntanetap’s potential to address a major unmet need for cognitive decline in Parkinson’s patients. The announcement underscores the company’s commitment to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to developing innovative therapies that improve patient outcomes and quality of life. The company’s platform targets multiple pathways involved in neurodegeneration, aiming to halt or reverse disease progression. The upcoming FDA meeting will be crucial for defining the regulatory path for buntanetap in PDD, a condition with limited treatment options.
For more information, visit Annovis Bio and follow the company on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
This development highlights the potential of buntanetap to address a significant unmet medical need, as there are currently no approved therapies specifically for cognitive decline in Parkinson’s disease. The FDA Type C meeting will allow Annovis to discuss clinical trial designs, endpoints, and other regulatory requirements necessary for advancing the drug toward approval. The company’s ongoing Phase 3 Alzheimer’s trial also remains on track, with regulatory alignment on key parameters.
Investors and stakeholders will be watching closely as Annovis prepares for the meeting, which could set the stage for pivotal trials in PDD. The company’s approach of targeting multiple neurodegenerative diseases with the same compound offers potential efficiencies in development and commercialization. With the FDA’s engagement, Annovis is positioned to make significant strides in addressing cognitive decline associated with Parkinson’s disease.
